(Total Views: 654)
Posted On: 12/11/2024 5:31:37 PM
Post# of 148866
Re: Evil Rabbit #148638
Would add: Clearance from the FDA to commence its Phase II oncology trial.
Engaging Syneos
Dr. Max Lataillade to Head of Clinical Development
Dr. Melissa Palmer, M.D., as Lead Consultant for Inflammation Studies with SMC Laboratories
Engaging Syneos
Dr. Max Lataillade to Head of Clinical Development
Dr. Melissa Palmer, M.D., as Lead Consultant for Inflammation Studies with SMC Laboratories
(10)
(0)Scroll down for more posts ▼
